{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Tyrosine+Kinase+Inhibitor+%28TKI%29&page=2", "query": { "intervention": "Tyrosine Kinase Inhibitor (TKI)", "page": 2 }, "page_size": 10 }, "pagination": { "page": 2, "page_size": 10, "total_count": 147, "total_pages": 15, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Tyrosine+Kinase+Inhibitor+%28TKI%29&page=3&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Tyrosine+Kinase+Inhibitor+%28TKI%29&page=1&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-10T15:31:57.370Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT02864251", "title": "A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor (TKI) Therapy", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Non-Small-Cell Lung Carcinoma" ], "interventions": [ { "name": "Nivolumab", "type": "BIOLOGICAL" }, { "name": "Ipilimumab", "type": "BIOLOGICAL" }, { "name": "Pemetrexed", "type": "DRUG" }, { "name": "Cisplatin", "type": "DRUG" }, { "name": "Carboplatin", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 367, "start_date": "2017-03-17", "completion_date": "2022-10-17", "has_results": true, "last_update_posted_date": "2023-09-28", "last_synced_at": "2026-10-10T15:31:57.370Z", "location_count": 18, "location_summary": "Long Beach, California • Los Angeles, California • Orange, California + 12 more", "locations": [ { "city": "Long Beach", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Orange", "state": "California" }, { "city": "Redondo Beach", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02864251" }, { "nct_id": "NCT01975519", "title": "A Phase 1B Dose-escalation and Phase 2a Study of Carotuximab (TRC105) in Combination With Pazopanib in Patients With Advanced Soft Tissue Sarcoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Advanced Soft Tissue Sarcoma" ], "interventions": [ { "name": "TRC105 and Pazopanib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Tracon Pharmaceuticals Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "12 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "12 Years to 120 Years" }, "enrollment_count": 111, "start_date": "2013-12-10", "completion_date": "2019-03-11", "has_results": true, "last_update_posted_date": "2020-05-20", "last_synced_at": "2026-10-10T15:31:57.370Z", "location_count": 9, "location_summary": "Birmingham, Alabama • Santa Monica, California • Jacksonville, Florida + 6 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Santa Monica", "state": "California" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Rochester", "state": "Minnesota" }, { "city": "Buffalo", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01975519" }, { "nct_id": "NCT01073436", "title": "Discontinuation of Imatinib Mesylate in Patients With Chronic-Phase Chronic Myeloid Leukemia Previously Treated With Interferon-Alpha", "overall_status": "TERMINATED", "study_type": "OBSERVATIONAL", "phases": [], "conditions": [ "Chronic Myeloid Leukemia" ], "interventions": [ { "name": "Discontinuation of therapy", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "University of Michigan Rogel Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 7, "start_date": "2009-05", "completion_date": "2011-11", "has_results": false, "last_update_posted_date": "2016-11-15", "last_synced_at": "2026-10-10T15:31:57.370Z", "location_count": 1, "location_summary": "Ann Arbor, Michigan", "locations": [ { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT01073436" }, { "nct_id": "NCT03875313", "title": "Study of CB-839 (Telaglenastat) in Combination With Talazoparib in Patients With Solid Tumors", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor", "Clear Cell Renal Cell Carcinoma", "TNBC - Triple-Negative Breast Cancer", "Colorectal Cancer", "CRC", "RCC", "ccRCC" ], "interventions": [ { "name": "CB-839", "type": "DRUG" }, { "name": "Talazoparib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Calithera Biosciences, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 33, "start_date": "2019-05-20", "completion_date": "2020-07-29", "has_results": true, "last_update_posted_date": "2022-02-17", "last_synced_at": "2026-10-10T15:31:57.370Z", "location_count": 9, "location_summary": "Birmingham, Alabama • Atlanta, Georgia • Iowa City, Iowa + 6 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT03875313" }, { "nct_id": "NCT02921477", "title": "Study for the Use of TKIs for Treatment of Cognitive Decline Due to Degenerative Dementias", "overall_status": "UNKNOWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Mild Cognitive Impairment", "Dementia" ], "interventions": [ { "name": "bosutinib", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Neurological Associates of West Los Angeles", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "45 Years", "maximum_age": "89 Years", "sex": "ALL", "summary": "45 Years to 89 Years" }, "enrollment_count": 150, "start_date": "2016-09", "completion_date": "2025-12-31", "has_results": false, "last_update_posted_date": "2022-09-28", "last_synced_at": "2026-10-10T15:31:57.370Z", "location_count": 1, "location_summary": "Santa Monica, California", "locations": [ { "city": "Santa Monica", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02921477" }, { "nct_id": "NCT07449936", "title": "COMO: A Phase 3 Randomized, Double-Masked Study Comparing the Efficacy of EYP-1901 Against Aflibercept in DME", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetic Macular Edema", "DME", "Diabetic Macular Edema (DME)" ], "interventions": [ { "name": "EYP-1901", "type": "DRUG" }, { "name": "Aflibercept (2.0 mg)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "EyePoint Pharmaceuticals, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 240, "start_date": "2026-02-16", "completion_date": "2028-10", "has_results": false, "last_update_posted_date": "2026-10-02", "last_synced_at": "2026-10-10T15:31:57.370Z", "location_count": 53, "location_summary": "Bakersfield, California • Encino, California • Glendale, California + 49 more", "locations": [ { "city": "Bakersfield", "state": "California" }, { "city": "Encino", "state": "California" }, { "city": "Glendale", "state": "California" }, { "city": "Mountain View", "state": "California" }, { "city": "Poway", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT07449936" }, { "nct_id": "NCT05160168", "title": "A Study of THE-630 in Patients With Advanced Gastrointestinal Stromal Tumors (GIST)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Gastrointestinal Stromal Tumors (GIST)", "Neoplasms, Connective Tissue", "Neoplasms, Connective and Soft Tissue", "Neoplasms by Histologic Type", "Neoplasms", "Gastrointestinal Neoplasms", "Digestive System Neoplasm", "Digestive System Disease", "Gastrointestinal Diseases" ], "interventions": [ { "name": "THE-630", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Theseus Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 32, "start_date": "2022-01-03", "completion_date": "2024-02-02", "has_results": true, "last_update_posted_date": "2024-06-05", "last_synced_at": "2026-10-10T15:31:57.370Z", "location_count": 7, "location_summary": "Scottsdale, Arizona • Jacksonville, Florida • Miami, Florida + 4 more", "locations": [ { "city": "Scottsdale", "state": "Arizona" }, { "city": "Jacksonville", "state": "Florida" }, { "city": "Miami", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT05160168" }, { "nct_id": "NCT04329325", "title": "Blinatumomab and Tyrosine Kinase Inhibitor Therapy in People With Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Acute Lymphoblastic Leukemia", "Philadelphia Chromosome-Positive" ], "interventions": [ { "name": "Blinatumomab", "type": "BIOLOGICAL" }, { "name": "dasatinib", "type": "DRUG" }, { "name": "dexamethasone", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Memorial Sloan Kettering Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 17, "start_date": "2020-03-30", "completion_date": "2027-03", "has_results": false, "last_update_posted_date": "2026-04-07", "last_synced_at": "2026-10-10T15:31:57.370Z", "location_count": 2, "location_summary": "New York, New York", "locations": [ { "city": "New York", "state": "New York" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT04329325" }, { "nct_id": "NCT04530565", "title": "Testing the Use of Steroids and Tyrosine Kinase Inhibitors With Blinatumomab or Chemotherapy for Newly Diagnosed BCR-ABL-Positive Acute Lymphoblastic Leukemia in Adults", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "B Acute Lymphoblastic Leukemia With t(9;22)(q34.1;q11.2); BCR-ABL1" ], "interventions": [ { "name": "Biospecimen Collection", "type": "PROCEDURE" }, { "name": "Blinatumomab", "type": "BIOLOGICAL" }, { "name": "Bone Marrow Aspiration and Biopsy", "type": "PROCEDURE" }, { "name": "Cyclophosphamide", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Dasatinib", "type": "DRUG" }, { "name": "Dexamethasone", "type": "DRUG" }, { "name": "Doxorubicin Hydrochloride", "type": "DRUG" }, { "name": "Echocardiography Test", "type": "PROCEDURE" }, { "name": "Electrocardiography", "type": "PROCEDURE" }, { "name": "Lumbar Puncture", "type": "PROCEDURE" }, { "name": "Mesna", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Multigated Acquisition Scan", "type": "PROCEDURE" }, { "name": "Ponatinib Hydrochloride", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Vincristine Sulfate", "type": "DRUG" } ], "intervention_types": [ "PROCEDURE", "BIOLOGICAL", "DRUG" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "75 Years", "sex": "ALL", "summary": "18 Years to 75 Years" }, "enrollment_count": 348, "start_date": "2021-01-25", "completion_date": "2028-07-01", "has_results": false, "last_update_posted_date": "2026-08-28", "last_synced_at": "2026-10-10T15:31:57.370Z", "location_count": 207, "location_summary": "Birmingham, Alabama • Anchorage, Alaska • Fort Smith, Arkansas + 145 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" }, { "city": "Anchorage", "state": "Alaska" } ], "official_url": "https://clinicaltrials.gov/study/NCT04530565" }, { "nct_id": "NCT03251378", "title": "A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors and Colorectal, and Breast Cancers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Solid Tumors", "Metastatic Colon Cancer", "Metastatic Breast Cancer", "Triple Negative Breast Cancer", "HER2-negative Breast Cancer", "Hormone Receptor Positive Breast Carcinoma", "Rectal Cancer" ], "interventions": [ { "name": "Fruquintinib (HMPL-013)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Hutchison Medipharma Limited", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 129, "start_date": "2017-12-11", "completion_date": "2023-03-30", "has_results": true, "last_update_posted_date": "2024-09-25", "last_synced_at": "2026-10-10T15:31:57.370Z", "location_count": 9, "location_summary": "Phoenix, Arizona • San Marcos, California • Santa Rosa, California + 6 more", "locations": [ { "city": "Phoenix", "state": "Arizona" }, { "city": "San Marcos", "state": "California" }, { "city": "Santa Rosa", "state": "California" }, { "city": "Aurora", "state": "Colorado" }, { "city": "Port Saint Lucie", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT03251378" } ] }